In last trading session, Halozyme Therapeutics Inc (NASDAQ:HALO) saw 3.66 million shares changing hands with its beta currently measuring 1.15. Company’s recent per share price level of $48.95 trading at $1.04 or 2.17% at ring of the bell on the day assigns it a market valuation of $6.03B. That closing price of HALO’s stock is at a discount of -44.02% from its 52-week high price of $70.50 and is indicating a premium of 14.18% from its 52-week low price of $42.01.

For Halozyme Therapeutics Inc (HALO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 1.2 in the current quarter.

Halozyme Therapeutics Inc (NASDAQ:HALO) trade information

Upright in the green during last session for gaining 2.17%, in the last five days HALO remained trading in the red while hitting it’s week-highest on Friday, 05/09/25 when the stock touched $48.95 price level, adding 30.0% to its value on the day. Halozyme Therapeutics Inc’s shares saw a change of 2.38% in year-to-date performance and have moved -27.73% in past 5-day. Halozyme Therapeutics Inc (NASDAQ:HALO) showed a performance of -20.12% in past 30-days.

Wall Street analysts have assigned a consensus price target of 62 to the stock, which implies a rise of 21.05% to its current value. Analysts have been projecting 62 as a low price target for the stock while placing it at a high target of 62. It follows that stock’s current price would drop -26.66% in reaching the projected high whereas dropping to the targeted low would mean a loss of -26.66% for stock’s current value.

Halozyme Therapeutics Inc (HALO) estimates and forecasts

This year revenue growth is estimated to rise 22.60% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 282.66M for the same. And 6 analysts are in estimates of company making revenue of 331.47M in the next quarter. Company posted 231.35M and 290.08M of sales in current and next quarters respectively a year earlier.

In 2025, company’s earnings growth rate is likely to be around 26.57% while estimates for its earnings growth in next 5 years are of 28.69%.

Halozyme Therapeutics Inc (NASDAQ:HALO)’s Major holders

BLACKROCK INC. is the top institutional holder at HALO for having 17.62 million shares of worth $922.58 million. And as of 2024-06-30, it was holding 13.8613 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 12.88 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.1336 of outstanding shares, having a total worth of $674.47 million.

On the other hand, iShares Trust-iShares Core S&P Mid-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025, the former fund manager was holding 4.16 shares of worth $203.42 million or 3.37% of the total outstanding shares. The later fund manager was in possession of 4.0 shares on Dec 31, 2024, making its stake of worth around $195.69 million in the company or a holder of 3.24% of company’s stock.